Spots Global Cancer Trial Database for A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Official Title: A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Study ID: NCT03555955
Study Description
Brief Summary: This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Georgetown University Medical Center, Washington, District of Columbia, United States
Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Weill Cornell Medical College, New York, New York, United States
New York Medical/Westchester, Valhalla, New York, United States
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Oregon Health and Science University, Portland, Oregon, United States
Baylor University Medical Center, Dallas, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Vancouver General Hospital, Vancouver, British Columbia, Canada
University Health Network/Princess Margaret Cancer Center, Toronto, Ontaro, Canada
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
